WO1999036545A3 - Adenoviral vectors with modified capsid proteins - Google Patents

Adenoviral vectors with modified capsid proteins Download PDF

Info

Publication number
WO1999036545A3
WO1999036545A3 PCT/US1999/000913 US9900913W WO9936545A3 WO 1999036545 A3 WO1999036545 A3 WO 1999036545A3 US 9900913 W US9900913 W US 9900913W WO 9936545 A3 WO9936545 A3 WO 9936545A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenoviral vectors
ligands
capsid proteins
target cells
modified capsid
Prior art date
Application number
PCT/US1999/000913
Other languages
French (fr)
Other versions
WO1999036545A2 (en
Inventor
Helen Romanczuk
Donna Armentano
Catherine R O'riordan
Original Assignee
Genzyme Corp
Helen Romanczuk
Donna Armentano
Riordan Catherine R O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Helen Romanczuk, Donna Armentano, Riordan Catherine R O filed Critical Genzyme Corp
Priority to AU23219/99A priority Critical patent/AU2321999A/en
Priority to JP2000540247A priority patent/JP2002508967A/en
Priority to EP99903122A priority patent/EP1044274A2/en
Priority to CA002317941A priority patent/CA2317941A1/en
Publication of WO1999036545A2 publication Critical patent/WO1999036545A2/en
Publication of WO1999036545A3 publication Critical patent/WO1999036545A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Abstract

The present invention is directed to adenoviral vectors having modified capsid proteins which comprise heterologous ligands that improve and/or alter the infectious capability of the vector. Such ligands are capable of binding to target cells, and their inclusion into adenoviral vectors facilitates the binding and infectious properties of the vectors. In a preferred embodiment, the ligands are peptides, and the target cells are epithelial cells. The invention is also directed to novel heterologous ligands, to ligand-receptor complexes, and to compositions comprising the adenoviral vectors of the invention. Additional aspects of the invention include methods to use the adenoviral vectors of the invention to deliver transgenes to target cells.
PCT/US1999/000913 1998-01-16 1999-01-15 Adenoviral vectors with modified capsid proteins WO1999036545A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU23219/99A AU2321999A (en) 1998-01-16 1999-01-15 Adenoviral vectors with modified capsid proteins
JP2000540247A JP2002508967A (en) 1998-01-16 1999-01-15 Adenovirus vector with modified capsid protein
EP99903122A EP1044274A2 (en) 1998-01-16 1999-01-15 Adenoviral vectors with modified capsid proteins
CA002317941A CA2317941A1 (en) 1998-01-16 1999-01-15 Adenoviral vectors with modified capsid proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7167498P 1998-01-16 1998-01-16
US60/071,674 1998-01-16

Publications (2)

Publication Number Publication Date
WO1999036545A2 WO1999036545A2 (en) 1999-07-22
WO1999036545A3 true WO1999036545A3 (en) 1999-11-04

Family

ID=22102858

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000913 WO1999036545A2 (en) 1998-01-16 1999-01-15 Adenoviral vectors with modified capsid proteins

Country Status (5)

Country Link
EP (1) EP1044274A2 (en)
JP (1) JP2002508967A (en)
AU (1) AU2321999A (en)
CA (1) CA2317941A1 (en)
WO (1) WO1999036545A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055365A1 (en) 1998-04-30 1999-11-04 Cornell Research Foundation, Inc. Adenoviral vectors with tandem fiber proteins
WO2000015823A1 (en) 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus
AU7085500A (en) * 1999-09-08 2001-04-10 Genzyme Corporation Adenoviral vectors modified for increased and persistent expression of the cystic fibrosis transmembrane conductance regulator gene in human airway epithelia
US6955808B2 (en) 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
ATE345819T1 (en) * 1999-09-24 2006-12-15 Uab Research Foundation CAPSID-MODIFIED RECOMBINANT ADENOVIRUS AND METHOD OF USE THEREOF
AU2001234981A1 (en) * 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
EP2368902A3 (en) * 2000-03-29 2011-12-21 DGI Bio Technologies LLC Insulin and IGF-1 receptor agonists and antagonists
JP2003534805A (en) * 2000-05-31 2003-11-25 ユニバーシティ オブ サスカチュワン Modified bovine adenovirus with altered affinity
AU2002250081A1 (en) * 2001-02-14 2002-08-28 Uab Research Foundation Combined transductional and transcriptional targeting system for improved gene delivery
CA2445626A1 (en) * 2001-04-17 2002-10-24 Vectorlogics, Inc. Mosaic adenoviral vectors
WO2002096939A2 (en) * 2001-05-30 2002-12-05 Transgene S.A. Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
WO2004108755A2 (en) * 2003-06-10 2004-12-16 University Of Saskatchewan Chimeric adenovirus capsid proteins
EP2036980A1 (en) * 2007-09-14 2009-03-18 Gruber, Jens Down regulation of gene expression using virus-like particles charged with nucleic acid
US20110104788A1 (en) * 2008-02-07 2011-05-05 Andrew Baker Modulation of Adenoviral Tropism
CZ301144B6 (en) * 2008-09-15 2009-11-18 Vysoká škola chemicko technologická v Praze Preparation of monoclonal antibodies against FoxP3 protein using modified virus resembling particles of Mason-Pfizer ape virus
ES2463966T3 (en) * 2010-04-28 2014-05-29 Institut Gustave Roussy Medical use of adenovirus vaccine vectors
CN102559758B (en) * 2011-12-16 2014-10-22 陕西师范大学 Vector for preparing adenovirus of which hexon is subjected to genetic modification and method for constructing vector
BR112014028684A2 (en) 2012-05-18 2017-07-25 Univ Pennsylvania simian subfamily and adenovirus a1302, a1320, a1331 and a1337 and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005201A1 (en) * 1993-08-13 1995-02-23 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1995026412A1 (en) * 1994-03-28 1995-10-05 The Uab Research Foundation Ligands added to adenovirus fiber
WO1997020051A2 (en) * 1995-11-28 1997-06-05 Genvec, Inc. Vectors and methods for gene transfer to cells
WO1997020575A1 (en) * 1995-12-08 1997-06-12 The University Of Alabama At Birmingham Research Foundation Targeted adenovirus vectors
WO1998022609A1 (en) * 1996-11-20 1998-05-28 Genzyme Corporation Chimeric adenoviral vectors
FR2761688A1 (en) * 1997-04-02 1998-10-09 Transgene Sa New adenovirus with mutations in the fibre protein to alter binding selectivity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005201A1 (en) * 1993-08-13 1995-02-23 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1995026412A1 (en) * 1994-03-28 1995-10-05 The Uab Research Foundation Ligands added to adenovirus fiber
WO1997020051A2 (en) * 1995-11-28 1997-06-05 Genvec, Inc. Vectors and methods for gene transfer to cells
WO1997020575A1 (en) * 1995-12-08 1997-06-12 The University Of Alabama At Birmingham Research Foundation Targeted adenovirus vectors
WO1998022609A1 (en) * 1996-11-20 1998-05-28 Genzyme Corporation Chimeric adenoviral vectors
FR2761688A1 (en) * 1997-04-02 1998-10-09 Transgene Sa New adenovirus with mutations in the fibre protein to alter binding selectivity

Also Published As

Publication number Publication date
JP2002508967A (en) 2002-03-26
WO1999036545A2 (en) 1999-07-22
CA2317941A1 (en) 1999-07-22
AU2321999A (en) 1999-08-02
EP1044274A2 (en) 2000-10-18

Similar Documents

Publication Publication Date Title
WO1999036545A3 (en) Adenoviral vectors with modified capsid proteins
EP1053013A4 (en) Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
WO2002061071A3 (en) Focused libraries of genetic packages
DE69826661D1 (en) ANTITUMORAL COMPILATION OF IMMUNOGENEOUS POLYPETIDES WITH CHANGED CELL LOCATION
ATE400656T1 (en) MINI-DYSTROPHIN NUCLEIC ACID AND PEPTIDE SEQUENCES
CA2285667A1 (en) Viral vectors having chimeric envelope proteins containing the igg-binding domain of protein a
WO2002096939A3 (en) Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
WO2001092547A3 (en) Modified bovine adenovirus having altered tropism
WO2001044809A3 (en) Evaluation of biological agents in living target cells
WO2001073028A3 (en) A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
WO1999055831A3 (en) Adenoviral vectors for treating disease
WO2000012710A8 (en) Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same
AUPM710194A0 (en) Virus vector
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
WO2002002148A3 (en) Dual recombinant gene therapy compositions and methods of use
IL146191A0 (en) Viral expression vectors
WO1998033929A3 (en) Use of a polypeptide as cell receptor for adenoviruses
WO2004108755A3 (en) Chimeric adenovirus capsid proteins
WO2001030966A3 (en) An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
WO2001083781A3 (en) 14094, a novel human trypsin family member and uses thereof
AU2176997A (en) Novel fused protein, gene therefor, recombinant vector, recombinant virus, and its use
WO2002002771A3 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
WO2002000857A3 (en) 53320, a human acyltransferase and uses therefor
AU5805798A (en) Recombinant adenoviral vector expressing antigens associated with colorectal tumors
WO2002006502A3 (en) Adenovirus vectors comprising introns

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 09582509

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2317941

Country of ref document: CA

Ref country code: CA

Ref document number: 2317941

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 540247

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 23219/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999903122

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999903122

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999903122

Country of ref document: EP